{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mangsbo SM"],"funding":["Science for Life Laboratory","Vetenskapsrådet","Lundblad family foundation","Svenska Sällskapet för Medicinsk Forskning","Region stockholm","Familjen Erling-Perssons Stiftelse","Knut och Alice Wallenbergs Stiftelse","Hjärt-Lungfonden","Jonas & Christina af Jochnick foundation"],"pagination":["e0258041"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8483319"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(9)"],"pubmed_abstract":["Numerous assays evaluating serological and cellular responses have been developed to characterize immune responses against SARS-CoV-2. Serological assays are both cost- and time-effective compared to cellular assays, but cellular immune responses may provide a diagnostic value to determine previous SARS-CoV-2 infection in seronegative individuals. However, potential cross-reactive T cell responses stemming from prior encounters with human coronaviruses (HCoVs) may affect assay specificity. In this study, we evaluated the specificity and sensitivity of a SARS-CoV-2 IFN-γ Release Assay (IGRA) based on the FluoroSpot method employing commercially available SARS-CoV-2-specific peptide pools, as well as an in-house designed SARS-CoV-2 peptide pool restricted to 5 amino acid stretches or less al"],"journal":["PloS one"],"pubmed_title":["An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses."],"pmcid":["PMC8483319"],"funding_grant_id":["2020-05880","2020-05782","20190468","2018-02552"],"pubmed_authors":["Lord M","Hober S","Lindsay R","Jernbom Falk A","Thalin C","Marking U","Lauren I","Buggert M","Christoffersson G","Phillipson M","Klingstrom J","Mangsbo SM","Havervall S","Nilsson P","Donnes P"],"additional_accession":[]},"is_claimable":false,"name":"An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses.","description":"Numerous assays evaluating serological and cellular responses have been developed to characterize immune responses against SARS-CoV-2. Serological assays are both cost- and time-effective compared to cellular assays, but cellular immune responses may provide a diagnostic value to determine previous SARS-CoV-2 infection in seronegative individuals. However, potential cross-reactive T cell responses stemming from prior encounters with human coronaviruses (HCoVs) may affect assay specificity. In this study, we evaluated the specificity and sensitivity of a SARS-CoV-2 IFN-γ Release Assay (IGRA) based on the FluoroSpot method employing commercially available SARS-CoV-2-specific peptide pools, as well as an in-house designed SARS-CoV-2 peptide pool restricted to 5 amino acid stretches or less al","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-03-16T15:46:19.139Z","creation":"2022-02-11T11:39:29.792Z"},"accession":"S-EPMC8483319","cross_references":{"pubmed":["34591918"],"doi":["10.1371/journal.pone.0258041"]}}